Cardiac Raptor Ablation Impairs Adaptive Hypertrophy, Alters Metabolic Gene Expression, and Causes Heart Failure in Mice

Background— Cardiac hypertrophy involves growth responses to a variety of stimuli triggered by increased workload. It is an independent risk factor for heart failure and sudden death. Mammalian target of rapamycin (mTOR) plays a key role in cellular growth responses by integrating growth factor and energy status signals. It is found in 2 structurally and functionally distinct multiprotein complexes called mTOR complex (mTORC) 1 and mTORC2. The role of each of these branches of mTOR signaling in the adult heart is currently unknown. Methods and Results— We generated mice with deficient myocardial mTORC1 activity by targeted ablation of raptor, which encodes an essential component of mTORC1, during adulthood. At 3 weeks after the deletion, atrial and brain natriuretic peptides and &bgr;-myosin heavy chain were strongly induced, multiple genes involved in the regulation of energy metabolism were altered, but cardiac function was normal. Function deteriorated rapidly afterward, resulting in dilated cardiomyopathy and high mortality within 6 weeks. Aortic banding–induced pathological overload resulted in severe dilated cardiomyopathy already at 1 week without a prior phase of adaptive hypertrophy. The mechanism involved a lack of adaptive cardiomyocyte growth via blunted protein synthesis capacity, as supported by reduced phosphorylation of ribosomal S6 kinase 1 and 4E-binding protein 1. In addition, reduced mitochondrial content, a shift in metabolic substrate use, and increased apoptosis and autophagy were observed. Conclusions— Our results demonstrate an essential function for mTORC1 in the heart under physiological and pathological conditions and are relevant for the understanding of disease states in which the insulin/insulin-like growth factor signaling axis is affected such as diabetes mellitus and heart failure or after cancer therapy.

[1]  M. Latronico,et al.  MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. , 2010, The Journal of clinical investigation.

[2]  E. Abel,et al.  Mammalian Target of Rapamycin Is a Critical Regulator of Cardiac Hypertrophy in Spontaneously Hypertensive Rats , 2009, Hypertension.

[3]  U. Eriksson,et al.  Myeloid Differentiation Factor-88/Interleukin-1 Signaling Controls Cardiac Fibrosis and Heart Failure Progression in Inflammatory Dilated Cardiomyopathy , 2009, Circulation research.

[4]  Y. Pinto,et al.  Avoidance of Transient Cardiomyopathy in Cardiomyocyte-Targeted Tamoxifen-Induced MerCreMer Gene Deletion Models , 2009, Circulation research.

[5]  R. Cooksey,et al.  Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. , 2009, Cardiovascular research.

[6]  P. Polak,et al.  mTOR and the control of whole body metabolism. , 2009, Current opinion in cell biology.

[7]  J. Blenis,et al.  Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy , 2009, Cell cycle.

[8]  M. Hall,et al.  mTOR-what does it do? , 2008, Transplantation proceedings.

[9]  Sang Gyun Kim,et al.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation , 2008, Proceedings of the National Academy of Sciences.

[10]  E. Casanova,et al.  Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. , 2008, Cell metabolism.

[11]  J. Auwerx,et al.  Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. , 2008, Cell metabolism.

[12]  M. Rubart,et al.  Cardiac Restricted Overexpression of Kinase-dead Mammalian Target of Rapamycin (mTOR) Mutant Impairs the mTOR-mediated Signaling and Cardiac Function* , 2008, Journal of Biological Chemistry.

[13]  V. Mootha,et al.  mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex , 2007, Nature.

[14]  Mi-Sung Kim,et al.  Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. , 2007, The Journal of clinical investigation.

[15]  J. P. McCoy,et al.  The Mammalian Target of Rapamycin (mTOR) Pathway Regulates Mitochondrial Oxygen Consumption and Oxidative Capacity* , 2006, Journal of Biological Chemistry.

[16]  Corinne Pellieux,et al.  Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway. , 2006, Journal of molecular and cellular cardiology.

[17]  A. Dart,et al.  Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis , 2006, Journal of hypertension.

[18]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[19]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[20]  D. Severson,et al.  Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. , 2006, Diabetes.

[21]  I. Shiojima,et al.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. , 2005, The Journal of clinical investigation.

[22]  William C Stanley,et al.  Myocardial substrate metabolism in the normal and failing heart. , 2005, Physiological reviews.

[23]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[24]  D. Severson,et al.  Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. , 2005, Canadian journal of physiology and pharmacology.

[25]  J. Robbins,et al.  Impact of beta-myosin heavy chain expression on cardiac function during stress. , 2004, Journal of the American College of Cardiology.

[26]  V. Giguère,et al.  Estrogen-Related Receptor α Directs Peroxisome Proliferator-Activated Receptor α Signaling in the Transcriptional Control of Energy Metabolism in Cardiac and Skeletal Muscle , 2004, Molecular and Cellular Biology.

[27]  J. Blenis,et al.  Deletion of Ribosomal S6 Kinases Does Not Attenuate Pathological, Physiological, or Insulin-Like Growth Factor 1 Receptor-Phosphoinositide 3-Kinase-Induced Cardiac Hypertrophy , 2004, Molecular and Cellular Biology.

[28]  M. Boluyt,et al.  The mTOR/p70S6K Signal Transduction Pathway Plays a Role in Cardiac Hypertrophy and Influences Expression of Myosin Heavy Chain Genes in vivo , 2004, Cardiovascular Drugs and Therapy.

[29]  S. Izumo,et al.  Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload , 2004, Circulation.

[30]  V. Giguère,et al.  Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. , 2004, Molecular and cellular biology.

[31]  E. Olson,et al.  Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.

[32]  W. Manning,et al.  Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice , 2003, Circulation.

[33]  F. Netter,et al.  Supplemental References , 2002, We Came Naked and Barefoot.

[34]  S. Cook,et al.  Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart* , 2002, The Journal of Biological Chemistry.

[35]  D. Severson,et al.  A Role for Peroxisome Proliferator-activated Receptor α (PPARα) in the Control of Cardiac Malonyl-CoA Levels , 2002, The Journal of Biological Chemistry.

[36]  R. Lerch,et al.  Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism. , 2001, Cardiovascular research.

[37]  M. Crackower,et al.  Temporally Regulated and Tissue-Specific Gene Manipulations in the Adult and Embryonic Heart Using a Tamoxifen-Inducible Cre Protein , 2001, Circulation research.

[38]  Tobias Schmelzle,et al.  TOR, a Central Controller of Cell Growth , 2000, Cell.

[39]  E. Lakatta,et al.  Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase. , 1997, Circulation research.

[40]  D. Kelly,et al.  Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. , 1996, Circulation.

[41]  A. Gingras,et al.  Rapamycin blocks the phosphorylation of 4E‐BP1 and inhibits cap‐dependent initiation of translation. , 1996, The EMBO journal.

[42]  J. Sadoshima,et al.  Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. , 1995, Circulation research.

[43]  J. Ross,et al.  ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. , 1994, The American journal of physiology.

[44]  H. Taegtmeyer Energy metabolism of the heart: from basic concepts to clinical applications. , 1994, Current problems in cardiology.

[45]  S. Shaughnessy,et al.  Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.